THERAPY DOSSIER · th-fe20539ba281

Bryostatin-1; brain-derived neurotrophic factor

Drug · No ChEMBL mechanism record; known protein kinase C (PKC) modulator

Evidence & regulatory context

Mechanism: No ChEMBL mechanism record; known protein kinase C (PKC) modulator
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL449158 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: Bryostatin 1; Bryostatin-1; NSC-339555
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00031694 ↗PHASE2completed

Sequential Paclitaxel and Bryostatin-1 for Advanced Pancreatic Cancer

Pancreatic Cancer

Enrolment: 19 · Results not recorded

NCT00005849 ↗PHASE2completed

Bryostatin-1 in Combination With Paclitaxel for Non-Small Cell Lung Cancer

Lung Cancer

Enrolment: 15 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23591125 ↗2013Reported benefit

Cerebral ischemia-induced difference in sensitivity to depression and potential therapeutics in rats.

RatIschaemia-reperfusionCerebral (MCAO/stroke)WistarMaleAcute administration during the induction phase; chronic bryostatin-1 given aft…

Model: Single episode of cerebral ischaemia followed by open space swim test to assess depressive behaviour

Acute BDNF or bryostatin-1 during induction reduced ischaemia-induced depressive sensitivity, and 5 weeks of bryostatin-1 reversed depressive immobility with a lasting effect persisting 3 weeks after treatment stopped, whereas alaproclate gave only temporary relief.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…